Programmed death‐ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV‐2 translational study... by Francesca Basso‐Valentina, Vincenzo Canzonieri, Rossella De Cecio, Laura Arenare, Domenica Lorusso, Sabrina Chiara Cecere, Eliana Pivetta, Daniela Russo, Annabella Di Mauro, Grazia Artioli, Anna Spina, Carmine De Angelis, Daniela Califano, Saverio Cinieri, Giosuè Scognamiglio, Vanda Salutari, Paolo Chiodini, Francesco Perrone, Sandro Pignata, Gustavo Baldassarre

Get full text

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer by Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, Maarit Anttila, David M O’Malley, Domenica Lorusso, Ashley F Haggerty, Michel Fabbro, John K Chan, Florian Heitz, Lyndsay J Willmott, Ilan Bruchim, Ying Zhuo, Purificacion Estevez-Garcia, Bradley J Monk, Hannelore Denys, Anja Knudsen, Anna V Tinker, Luis Manso Sanchez, Diane Provencher, Maria Pilar Barretina-Ginesta, John Hartman, Donna V Booth, Antonio Gonzalez-Martin